Portal de Periódicos da CAPES

Risk factors for vascular liver diseases

2020; Elsevier BV; Volume: 44; Issue: 4 Linguagem: Inglês

10.1016/j.clinre.2020.03.010

2210-741X

Juliette Soret, Dominique Debray, Flore Sicre de Fontbrune, Jean‐Jacques Kiladjian, David Saadoun, Régis Peffault de Latour, Dominique Valla, Virginia Hernández‐Gea, Sophie Hillaire, Danielle Dutheil, Aurélie Plessier, Christophe Bureau, Emmanuelle de Raucourt,

Hepatitis C virus research

Markers predicting complications of post-hepatitis C cirrhosis are needed. We asked whether changes in noninvasive markers of fibrosis can predict liver-related complications.This was a case-controlled study using a prospective national cohort (ANRS-CO12-CIRVIR) of 1323 HCV-infected patients with compensated cirrhosis: 97 patients who developed liver-related complications such as hepatocellular carcinoma or hepatic decompensation (cases) matched in age, sex and follow-up duration were compared with 257 patients without complications (controls). Actitest/Fibrotest™, Inflameter/Fibrometer™, ELF™ and Fibroscan™ were performed at baseline and yearly. Samples based on Propensity score matching were built and mixed linear models performed. Outcomes in a sustained virological response (SVR) negative population and a SVR-positive population were also described.At baseline, all characteristics of patients were similar between the groups. All fibrosis tests were statistically higher for cases compared to controls, Fibroscan™ excepted: Fibrotest™: 0.83 ± 0.13 vs. 0.77 ± 0.16; Fibrometer™: 0.93 ± 0.07 vs. 0.90 ± 0.11; ELF™: 11.4 ± 1.0 vs. 11.0 ± 1.2 (P < 0.02). The mean follow-up was 5.7 ± 1.9 years. Over a 3-year period, the significant difference in fibrosis marker values between cases and controls remained constant; with a trend toward a decrease in inflammation markers in controls, independent of SVR status.Baseline noninvasive serum fibrosis and inflammation markers were significantly higher in patients developing a complication than in controls. During the follow-up only inflammatory markers decreased in controls, but not in cases, and thus could potentially be used to predict the occurrence of complications in cirrhotic patients.